Oragenics, Inc. (OGEN)
OGENAMEXBiotechnology: Pharmaceutical Preparations
$0.3451
-0.0137 (-3.83%) today
Closed, Nov 9, 3:59 PM ET
- Market cap
- $1.58m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.3440 to $1.22
- Average volume
- 6.90m
- Previous close
- $0.3589
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.12m | -$2.50m | -$2.26m | -$2.59m |
| Net income | -$3.07m | -$2.29m | -$2.20m | -$2.53m |
News
8 latest- Oragenics Activates Third Site For Phase 2a Of ONP-002 In Treating Concussions, Data By Q4 '26 RTTNews · Jul 8, 2026
- Oragenics Advances Phase IIa Trial Of ONP-002 For Concussion RTTNews · Apr 20, 2026
- Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002 RTTNews · Apr 14, 2026
- Oragenics Kick Off Phase IIa Trial Operations For ONP-002; Stock Up RTTNews · Mar 12, 2026
- Oragenics Partners With Sterling For U.S.-Based Manufacturing Of Concussion Drug ONP-002 RTTNews · Jul 16, 2025
- Oragenics, Inc. Successfully Closes $16.5 Million Public Offering of Series H Convertible Preferred Stock and WarrantsQuiver Quantitative · Jul 2, 2025
- Oragenics, Inc. Announces $20 Million Public Offering of Series H Convertible Preferred Stock and WarrantsQuiver Quantitative · Jul 1, 2025
- Insider Sale: 10% owner at $OGEN Sells 5,000 SharesQuiver Quantitative · Jun 16, 2025
The company
Oragenics is a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology. The Company's lead candidate, ONP-002, is being developed as a potential first-in-class treatment for mTBI (concussion). Oragenics is advancing ONP-002 through Phase IIa clinical trials in Australia, with U.S. Phase IIb trials planned to follow pending IND submission. The Company's intranasal delivery platform has potential applications across a range of acute and chronic neurological conditions. For more information, visit www.oragenics.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- Region
- North America
- Website
- oragenics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.